The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
Open accessAbstract
Purpose: This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible (“unfit”) for cisplatin chemotherapy. Patients and Methods: The primary objective of the phase III part of this study was to compare the overall survival (OS) of chemotherapy-naive patients with measurable disease and an impaired renal function (glomerular filtration rate < 60 but > 30 mL/min) and/or performance score of 2 who were randomly assigned to receive either gemcitabine/carboplatin (GC) or methotrexate/carboplatin/vinblastine (M-CAVI). To detect an increase of 50% in median survival with GC compared with M-CAVI (13.5 v 9 months) based on a two-sided log-rank test at error rates α = .05 and β = .20, 225 patients were required. Secondary end points were overall response rate (ORR), progression-free survival (PFS), toxicity, and quality of life. Results: In all, 238 patients were randomly assigned by 29 institutions over a period of 7 years. The median follow-up was 4.5 years. Best ORRs were 41.2% (36.1% confirmed response) for patients receiving GC versus 30.3% (21.0% confirmed response) for patients receiving M-CAVI (P = .08). Median OS was 9.3 months in the GC arm and 8.1 months in the M-CAVI arm (P = .64). There was no difference in PFS (P = .78) between the two arms. Severe acute toxicity (death, grade 4 thrombocytopenia with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was observed in 9.3% of patients receiving GC and 21.2% of patients receiving M-CAVI. Conclusion: There were no significant differences in efficacy between the two treatment groups. The incidence of severe acute toxicities was higher for those receiving M-CAVI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Use of comprehensive geriatric assessment in older cancer patients:
Extermann, M., Aapro, M., Bernabei, R., Cohen, H. J., Droz, J.-P., Lichtman, S., Mor, V., Monfardini, S., Repetto, L., Sørbye, L., et al. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.06.003 · Cited by 1,098
Management of Cancer in the Older Person: A Practical Approach
Balducci, L., & Extermann, M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-224 · Cited by 939
Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., Herr, H., Higgins, G., & Boyle, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3173 · Cited by 728
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Dash, A., Galsky, M. D., Vickers, A. J., Serio, A. M., Koppie, T. M., Dalbagni, G., & Bochner, B. H. (2006) · Cancer · doi:10.1002/cncr.22031 · Cited by 435
Dogliotti, L., Cartenì, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., Amadori, D., Onat, H., & Marini, L. (2007) · European Urology · doi:10.1016/j.eururo.2006.12.029 · Cited by 330
Lorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
General guidelines for the management of older patients with cancer.
Balducci, L., & Yates, J. (2000) · PubMed · Cited by 275
Lichtman, S. M., Wildiers, H., Launay-Vacher, V., Steer, C., Chatelut, E., & Aapro, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.004 · Cited by 245
Bellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B., Sol�, L.-A., & Baselga, J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w · Cited by 228
Self-citationDe Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Skoneczna, I., Marreaud, S., de Wit, R., & Sylvester, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4924 · Cited by 169
Self-citationPetrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A., Salvestrini, F., Mondillo, S., & Francini, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<344::aid-cncr18>3.0.co;2-1 · Cited by 164
Wedding, U., Ködding, D., Pientka, L., Steinmetz, H. T., & Schmitz, S. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.05.001 · Cited by 127
Roehrig, B., Hoeffken, K., Pientka, L., & Wedding, U. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.10.001 · Cited by 70
Evidence-Based Management of Cancer in the Elderly
Balducci, L. (2000) · Cancer Control · doi:10.1177/107327480000700412 · Cited by 30
Santis, M. D., & Bachner, M. (2007) · Current Opinion in Urology · doi:10.1097/mou.0b013e3282c4b0cb · Cited by 23
Cited by
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Self-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Metadata
- Authors
- De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., Collette, S., Lorent, J., de Wit, R., & Sylvester, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-01-10
- Volume
- 30
- Issue
- 2
- Pages
- 191-199
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148562299
- Cited by
- 778
- References
- 20
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.